Skip to Content

Kenvue Inc KVUE

Morningstar Rating
$20.83 +0.29 (1.39%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Kenvue: Priced at $20 per Share as Part of Secondary Stock Offering for Johnson & Johnson

Wide-moat Kenvue announced late on May 14 that it had priced its secondary underwritten public offering of 182.3 million of its shares still owned by Johnson & Johnson at $20 apiece. We maintain our fair value estimate of $25.50 per share as we have made no changes to our model. Given where the stock is currently trading, we think $20 per share for the exchange is fairly priced, but we still believe that the market is underappreciating the firm’s portfolio of category-leading brands and that the stock has a lot of upside.

Price vs Fair Value

KVUE is trading at a 517% premium.
Price
$20.54
Fair Value
$54.50
Uncertainty
Medium
1-Star Price
$14.41
5-Star Price
$96.33
Economic Moat
Rvjkj
Capital Allocation
Rwmsscdk

Bulls Say, Bears Say

Bulls

With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business.

Bears

As rising input costs put pressure on Kenvue to hike prices, consumers could start to seek cheaper options or private label offerings, hurting Kenvue’s volumes.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KVUE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$20.54
Day Range
$20.5220.88
52-Week Range
$18.0927.76
Bid/Ask
$20.81 / $20.82
Market Cap
$39.91 Bil
Volume/Avg
12.5 Mil / 18.4 Mil

Key Statistics

Price/Earnings (Normalized)
15.96
Price/Sales
2.44
Dividend Yield (Trailing)
3.89%
Dividend Yield (Forward)
3.89%
Total Yield
3.93%

Company Profile

Kenvue is the world’s largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power.
Sector
Consumer Defensive
Industry
Household & Personal Products
Stock Style Box
Mid Core
Total Number of Employees
22,000

Competitors

Valuation

Metric
KVUE
KMB
PG
Price/Earnings (Normalized)
15.9619.5825.49
Price/Book Value
3.6743.587.98
Price/Sales
2.442.244.90
Price/Cash Flow
16.3614.9220.31
Price/Earnings
KVUE
KMB
PG

Financial Strength

Metric
KVUE
KMB
PG
Quick Ratio
0.640.470.40
Current Ratio
0.990.820.64
Interest Coverage
5.207.6720.66
Quick Ratio
KVUE
KMB
PG

Profitability

Metric
KVUE
KMB
PG
Return on Assets (Normalized)
5.96%13.44%13.82%
Return on Equity (Normalized)
13.54%303.53%35.61%
Return on Invested Capital (Normalized)
9.39%27.67%20.62%
Return on Assets
KVUE
KMB
PG
See how this stock stacks up to its competitors with Morningstar Investor

Household & Personal Products Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
PG
Procter & Gamble CoBkyrvkrmcsPlnz$391.2 Bil
UL
Unilever PLC ADRLzrhbhxpRscq$135.6 Bil
CL
Colgate-Palmolive CoKzhjmqwzlZjgzr$77.6 Bil
EL
The Estee Lauder Companies Inc Class AMmqypchqdLsdw$48.1 Bil
KMB
Kimberly-Clark CorpWfhsdpsxtQqhqs$45.2 Bil
RBGLY
Reckitt Benckiser Group PLC ADRKdkhrqtYyzvk$40.7 Bil
CHD
Church & Dwight Co IncVcrsmtfqQysm$26.2 Bil
CLX
Clorox CoTqqzzljlwBmjq$17.2 Bil
COTY
Coty Inc Class ABypgdWwdmy$9.4 Bil

Sponsor Center